Core Viewpoint - Jinshiyao expects a significant increase in net profit for the first three quarters, indicating strong business performance and effective cost management [1] Financial Performance - The net profit attributable to shareholders is projected to be between 86.61 million and 106.93 million yuan, representing a year-on-year increase of 48.99% to 83.95% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 69.13 million and 89.45 million yuan, with a year-on-year increase of 32.83% to 71.88% [1] - Non-recurring gains and losses are estimated to impact net profit by approximately 17.48 million yuan [1] Cost Management and Business Development - The company has implemented effective budget optimization and cost control measures, resulting in a year-on-year decrease in period expenses [1] - The new materials and machinery business segments have benefited from the successful commercialization of previous R&D projects, leading to improvements in both revenue and gross profit [1]

Core Viewpoint - The company expects a net profit of 86.61 million yuan for the first three quarters of 2025, representing a year-on-year increase of 48.99% [1] Financial Performance - The company has effectively implemented budget optimization and cost control measures, resulting in a year-on-year decrease in period expenses, which supports the stable development of its overall business [1] - The new materials and machinery business segments have benefited from the successful commercialization of certain R&D projects, leading to improvements in both revenue and gross profit compared to the previous year [1] - The estimated impact of non-recurring gains and losses on net profit for the reporting period is approximately 17.48 million yuan [1]

Sichuan Jinshi Asia Pharmaceutical Co., Ltd. 2025 Q1-Q3 Performance Forecast [I. Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company projects 2025 Q1-Q3 net profit to increase 48.99%-83.95%, reaching 86.61 million to 106.93 million yuan - The performance forecast period is from January 1, 2025, to September 30, 2025, with **net profit expected to be positive and increase year-on-year**[3](index=3&type=chunk) Key Financial Data for 2025 Q1-Q3 Performance Forecast | Indicator | Estimated Amount for Current Period (million yuan) | Year-on-Year Growth | Actual Amount for Same Period Last Year (million yuan) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 86.6055 — 106.9263 | 48.99% — 83.95% | 58.1291 | | Net Profit After Deducting Non-Recurring Gains/Losses | 69.1279 — 89.4488 | 32.83% — 71.88% | 52.0414 | [II. Communication with Accounting Firm](index=1&type=section&id=II.%20Communication%20with%20Accounting%20Firm) The performance forecast data is a preliminary estimate by the finance department and is unaudited by an accounting firm - The data related to this performance forecast has **not been audited by an accounting firm**[5](index=5&type=chunk) [III. Explanation of Performance Changes](index=1&type=section&id=III.%20Explanation%20of%20Performance%20Changes) Performance growth is attributed to budget optimization, lower period expenses, improved new materials and machinery business from R&D commercialization, and positive non-recurring gains - Through budget optimization and expense control, the company achieved a **year-on-year decrease in period expenses**, ensuring stable business development[6](index=6&type=chunk) - The new materials and machinery business segment saw **year-on-year improvements in revenue and gross profit** due to the successful commercialization of prior R&D projects[6](index=6&type=chunk) - During the reporting period, non-recurring gains and losses are expected to impact net profit by approximately **17.4776 million yuan**[6](index=6&type=chunk) [IV. Other Related Explanations](index=1&type=section&id=IV.%20Other%20Related%20Explanations) This performance forecast is a preliminary estimate, with detailed data in the 2025 Q3 report; investors are advised to note investment risks - This performance forecast is a **preliminary estimate** by the company's finance department, with specific data to be **detailed in the 2025 Q3 report**[7](index=7&type=chunk) - Investors are advised to make **cautious decisions** and be aware of **investment risks**[7](index=7&type=chunk) [V. Documents for Reference](index=1&type=section&id=V.%20Documents%20for%20Reference) The board of directors' explanatory statement on the 2025 Q1-Q3 performance forecast serves as a reference document - Documents for reference include the **board of directors' explanatory statement** on the 2025 Q1-Q3 performance forecast[8](index=8&type=chunk)

Group 1 - The stock price of Jinshi Asia Pharmaceutical increased by 2.00% on October 10, reaching 9.68 CNY per share, with a total market capitalization of 3.889 billion CNY [1] - Year-to-date, the stock price has risen by 18.32%, with a slight increase of 0.73% over the last five trading days, but a decline of 3.49% over the last 20 days and 3.39% over the last 60 days [1] - The company has seen a net inflow of 1.4607 million CNY from major funds, with significant buying and selling activity recorded [1] Group 2 - Jinshi Asia Pharmaceutical, established on July 15, 2004, and listed on April 24, 2015, is based in Chengdu, Sichuan, and Hangzhou, Zhejiang [2] - The company's main business includes the research, production, and sales of pharmaceuticals and health foods, with 82.76% of revenue coming from drug sales [2] - As of June 30, the number of shareholders increased by 14.00% to 22,800, while the average circulating shares per person decreased by 12.28% [2] Group 3 - Since its A-share listing, Jinshi Asia Pharmaceutical has distributed a total of 170 million CNY in dividends, with 71.9122 million CNY distributed over the past three years [3]

Core Viewpoint - Jinshi Yao (300434) has responded to investor inquiries on September 22, indicating that the company has disclosed the number of shareholders in its periodic reports, encouraging investors to pay attention to this information [1] Group 1 - The company has engaged with investors through an interactive platform [1] - The company emphasizes the importance of its periodic reports for shareholder information [1]

证券日报网讯金石亚药（300434）9月17日在互动平台回答投资者提问时表示，公司不涉及生产PBO材 料，目前正在进行PBO材料表面金属化处理的真空镀膜设备的研发工作。在研项目如果有实质性进展， 公司将会严格按照相关要求履行信息披露义务。 ...

2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议的召开情况 1、会议召开的时间 证券代码：300434 证券简称：金石亚药 公告编号：2025-038 四川金石亚洲医药股份有限公司 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形； （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 9 月 12 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00；通 过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 9 月 12 日 9:15-15:00 的任意时间。 2、现场会议召开地点：杭州市滨江区江南大道 4760 号亚科中心公司会议室 3、会议召开方式：本次股东会采取现场投票和网络投票相结合的方式 出席本次股东会现场会议和参加网络投票的股东及股东代理人共 132 人，代 表公司有表决权的股份数 200,547,262 股，占公司有表决权股份总数的 49.9192%。 4、会议 ...

金石亚药 2025 年第一次临时股东会法律意见书 北京天驰君泰（杭州）律师事务所 北京天驰君泰（杭州）律师事务所 关 于 四川金石亚洲医药股份有限公司 2025 年第一次临时股东会 法律意见书 北京天驰君泰（杭州）律师事务所 BEIJING TIANTAI LAW FIRM（HangZhou） 地址：浙江省杭州市滨江区西兴街道中海发展大厦 T3 六层 电话：86+0571-86681860 邮编：310052 二〇二五年九月 金石亚药 2025 年第一次临时股东会法律意见书 北京天驰君泰（杭州）律师事务所 北京天驰君泰（杭州）律师事务所 在本法律意见书中，本所律师根据本法律意见书出具日以前发生或存在的事 实及有关法律、行政法规、规范性文件及《公司章程》的规定，仅就本次股东会 召集和召开程序的合法有效性、出席会议人员资格和会议召集人资格的合法有效 性、会议表决程序和表决结果的合法有效性发表意见，而不对本次股东会所审议 的议案内容和该等议案中所表述的事实或数据的真实性和准确性发表意见。 本法律意见书仅供公司为本次股东会之目的而使用，不得被任何人用于其他 任何目的。本所同意，公司可以将本法律意见书作为公司本次股东会 ...

Core Insights - The company Jinshi Yiyao (300434) reported a total revenue of 492 million yuan for the first half of 2025, a decrease of 5.8% year-on-year, while the net profit attributable to shareholders increased by 67.71% to 65.74 million yuan [1] - The second quarter of 2025 showed a revenue of 200 million yuan, reflecting a year-on-year increase of 25.77%, and a net profit of 2.89 million yuan, up 105.72% year-on-year [1] - The company's profitability improved, with a slight increase in gross margin and a significant rise in net margin [1] Financial Performance - Total revenue for 2025 was 492 million yuan, down from 522 million yuan in 2024, marking a decline of 5.8% [1] - Net profit attributable to shareholders rose to 65.74 million yuan from 39.20 million yuan, an increase of 67.71% [1] - The gross margin was 56.89%, a slight increase of 0.05% year-on-year, while the net margin improved significantly to 13.09%, up 79.86% [1] - Total expenses (selling, administrative, and financial) amounted to 172 million yuan, accounting for 34.95% of revenue, down 8.62% year-on-year [1] Cash Flow and Assets - Cash and cash equivalents increased to 408 million yuan, a rise of 55.30% from 263 million yuan [1] - Accounts receivable rose to 107 million yuan, an increase of 18.44% from 90.76 million yuan [1] - The company’s interest-bearing debt surged to 133 million yuan, a significant increase of 403.44% from 26.37 million yuan [1] Earnings and Shareholder Metrics - Earnings per share (EPS) increased to 0.16 yuan from 0.10 yuan, reflecting a growth of 67.73% [1] - The net asset value per share rose to 6.19 yuan, up 3.78% from 5.96 yuan [1] - Operating cash flow per share improved significantly to 0.37 yuan from -0.22 yuan, a rise of 265.86% [1] Business Evaluation - The company's return on invested capital (ROIC) was 3.32%, indicating weak capital returns [3] - The historical median ROIC since listing is 6.74%, with a notably poor performance in 2020, where ROIC was -28.39% [3] - The company's business model relies heavily on marketing, necessitating further investigation into the underlying drivers of this approach [3] - The accounts receivable situation is concerning, with accounts receivable to profit ratio reaching 117.15% [3]

Group 1 - The core viewpoint of the article is that Jinshi Yao (300434.SZ) reported a decrease in revenue for the first half of 2025, while net profit showed significant growth [1] Group 2 - The company's operating revenue for the first half of 2025 was 492 million yuan, representing a year-on-year decrease of 5.80% [1] - The net profit attributable to shareholders of the listed company was 65.74 million yuan, reflecting a year-on-year increase of 67.71% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 55.72 million yuan, which is a year-on-year increase of 50.45% [1] - The basic earnings per share were 0.1637 yuan [1]